Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A-Reference-Cited by-同舟云学术

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A

Published:2014-01-16 Issue:3 Volume:123 Page:317-325
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Mahlangu Johnny¹,Powell Jerry S.²,Ragni Margaret V.³,Chowdary Pratima⁴,Josephson Neil C.⁵,Pabinger Ingrid⁶,Hanabusa Hideji⁷,Gupta Naresh⁸,Kulkarni Roshni⁹,Fogarty Patrick¹⁰,Perry David¹¹,Shapiro Amy¹²,Pasi K. John¹³,Apte Shashikant¹⁴,Nestorov Ivan¹⁵,Jiang Haiyan¹⁵,Li Shuanglian¹⁵,Neelakantan Srividya¹⁵,Cristiano Lynda M.¹⁵,Goyal Jaya¹⁵,Sommer Jurg M.¹⁵,Dumont Jennifer A.¹⁵,Dodd Nigel¹⁵,Nugent Karen¹⁵,Vigliani Gloria¹⁵,Luk Alvin¹⁵,Brennan Aoife¹⁵,Pierce Glenn F.¹⁵

Affiliation:

1. Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa;

2. University of California at Davis, Davis, California;

3. University of Pittsburgh and the Hemophilia Center of Western Pennsylvania, Pittsburgh, PA;

4. Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free Hospital, London, United Kingdom;

5. Puget Sound Blood Center, Seattle, WA;

6. Universitätsklinik für Innere Medizin I, Medizinische Universität Wien, Wien, Austria;

7. Department of Hematology, Ogikubo Hospital, Suginami-ku, Tokyo, Japan;

8. Haemophilia Centre and Department of Medicine, Maulana Azad Medical College & Associated Lok Nayak Jai Prakash Narayan Hospital, New Delhi, India;

9. Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI;

10. Penn Comprehensive Hemostasis and Thrombosis Program, Hospital of the University of Pennsylvania, Philadelphia, PA;

11. Cambridge Haemophilia & Thrombosis Centre, Addenbrooke’s Hospital, Cambridge, United Kingdom;

12. Indiana Hemophilia and Thrombosis Center, Department of Hematology, Indianapolis, IN;

13. Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom;

14. Sahyadri Hospital, Department of Hematology, Mahara, India; and

15. Biogen Idec Hemophilia, Cambridge, MA

Abstract

Key Points A novel recombinant factor VIII with prolonged half-life, rFVIIIFc, was developed to reduce prophylactic injection frequency. rFVIIIFc was well-tolerated in patients with severe hemophilia A, and resulted in low bleeding rates when dosed 1 to 2 times per week.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/3/317/1377512/317.pdf

Reference29 articles.

1. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics [published online ahead of print October 24, 2013].;Rath

2. National Hemophilia Foundation MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Available at:http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed July 18, 2013

3. Improvements in factor concentrates.;Lillicrap;Curr Opin Hematol,2010

4. Barriers to compliance with prophylaxis therapy in haemophilia.;Hacker;Haemophilia,2001

Cited by 391 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A post hoc comparative real‐world analysis of HEAD‐US score for joint health assessment of patients with severe haemophilia A and B in Spain;Haemophilia;2024-01-28

2. Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment;Seminars in Thrombosis and Hemostasis;2024-01-15

3. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single‐center experience in Bangladesh;eJHaem;2024-01-09

4. Efficacy and safety of adeno-associated virus-based clinical gene therapy for hemophilia: A systematic review and meta-analysis;Human Gene Therapy;2024-01-07

5. Comparison of one‐stage and chromogenic factor VIII assays to tailor the dose of recombinant factor VIII‐Fc fusion protein (rFVIIIFc, efmoroctocog alfa) in adult patients with haemophilia A: Single‐centre, real‐world experience of surgery;Haemophilia;2023-12-27